YT-19 / BriSTAR Immunotech - LARVOL DELTA

Safety and Efficacy of Allogeneic anti-CD19 STAR-T cell in Severe/Refractory Autoimmune Diseases: A phase I trial (EULAR 2026) - P=N/A | "After fludarabine/cyclophosphamide lymphodepletion, patients received YTS109. Conclusions YTS109 demonstrated a favorable safety profile and elicited broad, system-level immunomodulation beyond B-cell depletion. Updated results will be presented."

Clinical • P1 data • Fibrosis • Glomerulonephritis • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • HLA-B

CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Hebei Yanda Ludaopei Hospital | Recruiting ➔ Completed

Trial completion • Hematological Malignancies • Oncology • CD19

[VIRTUAL] A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL) (ASH 2020) - P1 | "Here, we report pre-clinical and first-in-human phase I trial results of CD19 STAR-T cell therapy for CD19+ R/R B-ALL...Patients received a conditioning regimen of IV fludarabine (25mg/m2/d) and cyclophosphamide (250mg/m2/d) for 3 days followed by a single STAR T-cell infusion...A high CR could be achieved on day 14 with low toxicity. Longer-term observation of these patients and studies of larger patient cohorts are warranted."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD19